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Summary 
Neutrophils are key components of the innate immune response, providing host 
defence against infection and being recruited to non-microbial injury sites. 
Platelets act as a trigger for neutrophil extravasation to inflammatory sites but 
mechanisms and tissue-specific aspects of these interactions are currently 
unclear. Here, we use bacterial endotoxin in mice to trigger an innate 
inflammatory response in different tissues and measure neutrophil invasion with 
or without platelet reduction. We show that platelets are essential for neutrophil 
infiltration to the brain, peritoneum and skin, neutrophil numbers returning to 
basal levels in the peritoneum and skin and being decreased (~60%) in the 
brain when platelets are reduced. In contrast neutrophil infiltration in the lung is 
unaffected by platelet reduction, up-regulation of CXCL-1 (2.4-fold) and CCL5 
(1.4-fold) acting as a compensatory mechanism in platelet-reduced mice during 
lung inflammation. In brain inflammation targeting platelet receptor GPIbα 
results in a significant decrease (44%) in platelet-mediated neutrophil invasion, 
whilst maintaining platelet numbers in the circulation. These results suggest that 
therapeutic blockade of platelet GPIbα could limit the harmful effects of 
excessive inflammation while minimising haemorrhagic complications of platelet 
reduction in the brain. The data also demonstrate the ability to target damaging 
brain inflammation in stroke and related disorders without compromising lung 
immunity and hence risk of pneumonia, a major complication post-stroke. In 
summary, our data reveal an important role for platelets in neutrophil infiltration 
to various tissues, including the brain, and so implicate platelets as a key, 
targetable component of cerebrovascular inflammatory disease or injury. 
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Introduction 
The innate immune response provides rapid defence against infection, injury or 
disease. Neutrophils are the primary cellular response unit during the initial 
stages of these challenges and are essential for the destruction or removal of 
inciting stimuli (1). However, prolonged or excessive neutrophil mediated 
inflammation is injurious to adjacent healthy tissue in many situations, and is 
especially harmful during central nervous system (CNS) inflammation where 
capacity for repair is limited (2). An interaction with platelets is essential to 
trigger the tethering and rolling of neutrophils on inflamed venules, before their 
extravasation (3). Activated platelets attach to neutrophils via the release and 
surface expression of platelet P-selectin from α-granules which binds to PSGL-1 
expressed on neutrophils (4). After CNS injury, a dense neutrophil invasion 
occurs (5-7), and selectively abrogating neutrophil infiltration is beneficial in 
animal models of stroke and experimental autoimmune encephalomyelitis (6,8). 
We have shown that mechanisms of neutrophil invasion following an innate 
immune challenge can be unique to their target tissue, allowing for tissue 
specific anti-inflammatory interventions (9). This may be especially important 
when targeting components of the immune system that are particularly 
susceptible to infections, such as after stroke and spinal cord injury (10,11). 
Here we assessed the contribution of platelets to neutrophil-mediated 
inflammation across a variety of tissue beds, to investigate tissue-specific 
mechanisms of innate immunity, as we have previously shown in the context of 
interleukin-1 (IL-1) (9). Furthermore, we investigated whether platelet-
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dependent neutrophil infiltration could be blocked, without reducing platelet 
numbers and increasing the risk of haemorrhage after cerebral inflammation. 
 
Materials and Methods 
Animals 
Experiments were performed on male 8-10 week-old wild-type (WT) C57BL/6 
mice (Harlan Laboratories, Bicester, UK) under appropriate UK Home Office 
licences and adhered to the UK Animals (Scientific Procedures) Act 1986. 
 
Inflammatory challenge 
Peritoneal inflammation model: Mice were injected intraperitoneally with 1mg/kg 
lipopolysaccharide (LPS) from Escherichia coli O127:B8 (Sigma-Aldrich, Dorset, 
UK) or vehicle (phosphate buffered saline (PBS)) in a volume of 8 ml/kg. At 6 h 
peritoneal lavage was performed using 5 ml of lavage buffer (PBS containing 
0.1% BSA and 1mM EDTA). Neutrophils in lavage fluid were quantified using 
Coulter Counter and haemocytometry measurements, combined with flow 
cytometry (see below). 
Broncho-alveolar inflammation model: Mice were exposed to aerosolised LPS 
(2 mg/ml) or vehicle (saline) for 20 min via a nebuliser chamber. At 6 h broncho-
alveolar lavage was performed, via direct cannulation of the trachea, with 1 ml 
of lavage buffer. 
Air-pouch inflammation model: Dorsal air-pouches were created in conscious 
mice as described previously (12). At day 7, 1 ml of LPS (1 mg/ml) or vehicle 
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(PBS) was injected into the air-pouch. After 6 h air-pouch lavage was performed 
using 4 ml lavage buffer. 
Cerebral inflammation model: Animals were anaesthetised with isoflurane (3%) 
in O2 (200 ml/min) and N2O (400 ml/min) and placed securely in a small animal 
stereotaxic frame (Stoetling, Illinois, USA). After craniotomy, mice were injected 
intracerebrally with 1 µl LPS (4 mg/ml), via a glass micro-needle (co-ordinates 
from bregma: anterior-posterior -0.0 mm, lateral -2.0 mm, ventral -2.5 mm. Rate 
= 0.5 µl/min). The micro-needle was left in situ for 2 min following the injection. 
Mice were transcardially perfused with saline at 6 h and brain tissue collected 
for cytometric bead array (CBA) analysis or perfuse-fixed (saline followed by 
paraformaldehyde 4%) at 24 h for tissue sectioning. 
Platelet reduction: Mice were injected i.p with anti-CD41 antibody (1 mg/kg) or 
IgG isotype control (1 mg/kg) 24 h prior to inflammatory challenge. Tail vein 
blood samples taken at 0, 18 and 24h post-injection were analysed via flow 
cytometry to quantify circulating platelets. To determine the effect of the 
antibody on circulating leukocyte populations, cardiac blood sampled prior to 
sacrifice at 48h post-injection underwent flow cytometric analysis (see below) to 
quantify the populations of various leukocytes. Platelet numbers were reduced 
by (~70%; Figure 1A) with no significant effect on circulating leukocytes (data 
not shown). To block platelet-endothelium interactions without any reduction in 
platelets, an anti-GpIbα Fab fragment (p0p/B) or isotype control IgG were 
injected i.p (4 mg/kg) 4 h before intrastriatal injection of LPS. Anti-GpIbα 
treatment had no effect on numbers of circulating neutrophils (data not shown). 
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Flow cytometry 
Lavage fluid (200 µl) or blood (50µl blood + 50µl buffer: 0.1% BSA, 1mM EDTA 
in PBS) samples were incubated for 20 min with 1:200 rat anti-mouse 
CD16/CD32 to block non-specific Fc binding. Cocktails of fluorophore-
conjugated antibodies were added for 30 min, to detect Ly-6G, Ly-6C, CD45, 
B220, CD3, MHC-2, Gr-1, CD11b, CD115, CD41 and CD61. Red blood cells in 
samples were lysed by the addition of 450ml FACS Lysing Solution (BD 
Biosciences, Oxford, UK). Absolute numbers of cells were determined through 
the use of TruCOUNT™ tubes (BD Biosciences, Oxford, UK), or by the addition 
of 50 µl fluorescent counting beads (inVitrogen, Paisley, UK). Flow cytometry 
was performed on a CyAn™ ADP Flow Cytometer (Dako UK Ltd, Ely, UK) 
equipped with 405, 488 and 633 nm lasers using Summit 4.0 software. Cell 
populations were determined on Summit 4.0 software via positive labelling of 
relevant markers. For blood samples, a minimum of 1000 beads, 1,000 
neutrophils or 5,000 leukocytes (whichever threshold occurred last) were 
acquired per sample. For lavage samples, a minimum of 20,000 cellular events 
were acquired per sample.  
 
Immunostaining 
Total cell numbers in brain tissue sections were determined via microscopy 
following immunohistochemistry staining. Anti-neutrophil (SJC4, rabbit anti-
mouse) primary antibody (1:50,000; kindly provided by Professor Daniel 
Anthony, University of Oxford, UK) was used to stain for neutrophils. 
Neutrophils were quantified in three regions (cortex, injection site and ventral 
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striatum) using a 10x10 mm graticule at 20x magnification. Cerebrovascular 
activation was determined by the expression of vascular cellular adhesion 
molecule-1 (VCAM-1, goat anti-mouse primary antibody, 1:250; R&D systems, 
UK). 
 
Cytometric bead array 
Cytokine concentrations in plasma and lavage samples were determined using 
mouse-specific CBA flex sets (BD Pharmingen, UK). CBA was used to quantify 
IL-1α, IL-1β, IL-6, TNFα, CXCL1, and CCL5 following the manufacturer’s 
recommended protocol. Acquisition was undertaken using a BD FACSArray™ 
Bioanalyzer System (BD Biosciences, UK), and results determined using FCAP 
Array™ software (Soft Flow, Minnesota, USA). 
 
Statistics 
Data are expressed as mean (± sem). Differences between groups were 
analysed using one-way ANOVA with Bonferroni’s correction for multiple 
comparisons post-hoc. Differences were considered statistically significant at 
p<0.05. 
 
Results 
Platelets are essential for neutrophil invasion to the peritoneum, skin and brain, 
but not lung after LPS-induced inflammation 
Until recently, the precise mechanism of platelet-neutrophil interaction in vivo 
during innate immune responses was unclear. However, Sreeramkumar and co-
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workers recently described platelet-neutrophil dynamics in inflamed cremaster 
blood vessels, showing platelets are key to initiating the process of neutrophil 
tethering, rolling and crawling upon vessels (3). To determine if platelets are 
required to drive innate immune responses in other tissues we stimulated 
inflammation with the bacterial endotoxin, LPS, in mice with a reduction in 
platelets. We used the accumulation of neutrophils as a measure of the intensity 
of the inflammatory reaction and assessed this at time-points coinciding with 
peaks of neutrophil influx established previously for the respective tissues (9). 
LPS stimulated significant increases in neutrophil accumulation in lavage fluid 
from the peritoneum (4-fold), air-pouch (~3-fold), lung (~13-fold) and in the brain 
(~23-fold) (Figure 1). In contrast, after platelet reduction, neutrophil recruitment 
was completely blocked in peritoneum (96%; Figure 1B) and air-pouch (100%; 
Figure 1C), and significantly reduced (66%) in the brain (Figure 1D), showing 
platelet dependent neutrophil infiltration for the first time in these tissues.  
Redundancy of innate immune response mechanisms is an evolutionary 
advantage to tissues exposed to a wide variety of pathogens, such as the lung. 
Here, in contrast to peritoneum, air-pouch and brain, which are exposed to 
lower pathogenic load, we saw no effect of platelet reduction on neutrophil 
invasion after LPS-induced inflammation in the lung (Figure 1E), showing 
platelet-independent mechanisms of neutrophil invasion. 
LPS injection in the peritoneum resulted in a significant increase (~2.5 fold) in 
the number of circulating neutrophils at 6h after injection, with anti-CD41 
treatment having no effect on this increase (data not shown). In contrast LPS 
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when administered in the air-pouch, lung and brain did not affect circulating 
neutrophil numbers at 6h (data not shown). 
 
Upregulation of CXCL1 and CCL5 in the inflamed lung counterbalance the 
effects of platelet reduction 
To further investigate tissue specific-mechanisms at each site of inflammation, 
the cytokines IL-1α, IL-1β, IL-6, TNF and chemokines CXCL1 and CCL5, which 
are important for neutrophil recruitment (14), were measured with or without 
platelet reduction. LPS induced a similar profile of inflammation across all tissue 
sites (Figure 2). The inflammatory mediators measured were unaffected by 
platelet reduction in the peritoneum, air-pouch and brain (Figure 2). In contrast, 
with platelet reduction during lung inflammation, which failed to attenuate 
neutrophil recruitment, we found significant increases in the neutrophil 
chemoattractant CXCL1 (2.4-fold), and CCL5 (1.4-fold) in lung lavage fluid in 
animals with reduced platelets compared to IgG controls, and a non-significant 
increase in the pro-inflammatory cytokine TNF (Figure 2). 
 
Targeting of platelet GPIbα reduces neutrophil infiltration to the brain 
The innate immune system is essential for host defence but excessive or 
prolonged neutrophil-mediated inflammation is also associated with injury and 
disease, especially in the brain (2). The above data provide evidence for 
platelet-dependent neutrophil infiltration in three different tissue beds. However, 
depleting platelets as an approach to reduce inflammation has important 
limitations due to increasing vulnerability to haemorrhage. Therefore, to assess 
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whether platelet-dependent neutrophil infiltration could be blocked, in a manner 
with less potential systemic effects and therefore more relevant therapeutically 
and without reducing platelet numbers, we administered anti-GpIbα antibody in 
the context of LPS-induced brain inflammation. Anti-GpIbα antibody has been 
shown previously to protect mice from ischemic brain injury in an experimental 
stroke model without an increase in bleeding complications (15). Here, anti-
GpIbα antibody had no effect on numbers of circulating platelets compared to 
IgG-injected controls (Figure 3A) yet significantly reduced (44%) the number of 
neutrophils in brain tissue after LPS (Figure 3B-C). We saw no effect of the anti- 
GpIbα antibody on endothelial activation, as assessed by VCAM-1 staining 
(Figure 3C). 
 
Discussion 
Neutrophil invasion to the brain is significantly reduced in mice lacking IL-1 (9), 
as it is here in mice with reduced numbers of platelets. Furthermore, we have 
shown previously that platelet-derived IL-1 drives endothelial activation in vitro, 
suggesting a convergence of brain and platelet-derived IL-1 effects on the 
endothelium. 
These data replicate findings from Sreeramkumar et al., where only LPS plus 
an anti MHC-I antibody produced a strong enough lung inflammation to be 
attenuated by platelet intervention, as LPS-induced inflammation alone was 
unaffected by blocking of platelet activity (3). Together, these findings provide 
further evidence for tissue specific-mechanisms of innate immunity and highlight 
the flexibility of the lungs in dealing with pathogen-driven inflammation. 
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These data suggest the implementation of compensatory mechanisms specific 
to the lung in the absence of platelets, which would be advantageous to a site of 
such pathogenic exposure and explain the maintenance of neutrophil 
recruitment, despite platelet reduction. 
Targeting neutrophil invasion during CNS injury may have therapeutic benefit as 
we, and others, have shown neutrophil mediated neurotoxic effects after stroke 
(6,16). Indeed, neutrophils have neurotoxic effects on neurones in vitro (17), an 
effect that appears dependent on phenotypic changes that occur during 
neutrophil cerebrovascular infiltration (18). Targeting various aspects of platelet 
activation reduces stroke injury (3,15,19). This, together with platelet-dependent 
neutrophil infiltration mechanisms (3) and the relevance of these in different 
tissues shown here, suggests that platelet targeted therapies may be beneficial 
after CNS injury. 
A potential limitation of any immune-modulatory approach to treating acute CNS 
inflammatory conditions is the potential for increased risk of systemic infectious 
complications, notably in conditions such as stroke and head trauma. 
Pneumonia is the most common cause of infection in these patients and since 
the innate immune response in the lung is platelet-independent, in contrast to 
the brain, this may offer a relatively targeted approach to inhibiting damaging 
CNS inflammation without overly compromising respiratory anti-microbial innate 
immunity. Platelets adhere to hypoxic endothelial cells by binding of their GpIbα 
receptor to von Willebrand factor on the endothelial surface (20). Targeting this 
interaction may limit the time platelets spend at the endothelium and reducing 
the number of physical interactions with neutrophils, whilst concomitantly 
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reducing the ability of platelets to activate the endothelium, which is partly 
responsible for driving cerebrovascular inflammation (13). Therefore, targeting 
of the platelet GpIbα receptor is a potential therapeutic strategy for reducing 
neutrophil-mediated CNS injury. 
In conclusion we show here that platelets are essential for neutrophil 
extravasation to inflammatory sites, but that this is dependent on specific tissue 
location. We show that platelets are essential for neutrophil infiltration to the 
peritoneum, skin and brain, but not the lung, where compensatory mechanisms 
allow for greater flexibility when dealing with pathogen. We also specifically 
show that platelet-mediated neutrophil invasion to the brain is dependent upon 
the receptor GPIbα which can be targeted to limit excessive inflammation while 
retaining platelet numbers and reducing the risk of haemorrhage in the brain. 
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Figure legends 
Figure 1. (A) Characterisation of platelet reduction via anti-CD41 antibody. Anti-
CD41 antibody or IgG control were administered intraperitoneally. Blood was 
sampled via tail vein sampling at 0, 18 and 24h post-injection. Quantification of 
platelets was carried out via flow cytometry using BD TruCOUNT™ tubes. 
Individual data points are presented as a scatter graph with the mean ± SEM 
shown. ***p<0.001; one-way ANOVA with Bonferroni’s correction. (B-E) 
Neutrophil infiltration to the peritoneum, skin and brain is platelet dependent 
after LPS-induced inflammation. The innate immune response was triggered by 
LPS challenge in four different tissues four hours after mice had received either 
anti-CD41 antibody or control IgG (1 mg/kg), and neutrophil accumulation was 
measured. Neutrophil infiltration is dependent on platelets during inflammation 
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in (B) the peritoneum, (C) subcutaneous air pouch and (D) Brain. Conversely, 
(E) neutrophil infiltration to the lung is not affected by platelet reduction after 
LPS injection. *p<0.05, **p<0.01, ***p<0.001; one-way ANOVA with 
Bonferroni’s correction. Individual data points are presented as a scatter graph 
with the mean ± SEM shown. 
 
Figure 2. Chemokines CXCL1 and CCL5 in the inflamed lung are upregulated 
as compensatory mechanisms in response to platelet reduction. The cytokines 
IL-1α, IL-1β, IL-6, TNF and chemokines CXCL1 and CCL5 concentrations were 
measured in lavage fluid of peritoneum, air pouch and lung, or homogenised 
brain tissue after LPS challenge, in mice that had received either anti-CD41 
antibody or control IgG. LPS induced a similar profile of inflammation across all 
tissue sites and was unaffected by platelet reduction in peritoneum, air pouch 
and brain. During inflammation, platelet reduction induced a significant increase 
in CXCL1 and CCL5 in lung lavage fluid. *p<0.05, **p<0.01, ***p<0.001; one-
way ANOVA with Bonferroni’s correction. Individual data points are presented 
as a scatter graph with the mean ± SEM shown. 
 
Figure 3. Non-depleting targeting of platelets reduces neutrophil infiltration to 
the brain. Anti-GpIbα antibody or IgG control were administered (4 mg/kg i.p) 4 
hours before LPS-induced brain inflammation. Anti-GpIbα antibody had no 
effect on numbers of circulating platelets compared to IgG-injected controls (A) 
yet significantly reduced the number of neutrophils in brain tissue compared to 
IgG control during inflammation (B). Representative immunofluorescence 
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staining of reduced neutrophil numbers in the brain striatum following LPS 
injection in the presence of the anti-GpIbα antibody versus IgG control, which 
were not accompanied by any change in cerebrovascular activation (VCAM-1 
statining) (C). **p<0.01, ***p<0.001; one-way ANOVA with Bonferroni’s 
correction. Individual data points are presented as a scatter graph with the 
mean ± SEM shown. Scale bar = 200µm. 
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